-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $32

Benzinga·12/09/2025 17:57:46
Listen to the news
B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $29 to $32.